Free Trial

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

-0.01 (-0.15%)
(As of 05/29/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.30 million shs
Average Volume
1.38 million shs
Market Capitalization
$2.09 billion
P/E Ratio
Dividend Yield
Price Target

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
21.7% Upside
$8.25 Price Target
Short Interest
2.76% of Float Sold Short
Dividend Strength
News Sentiment
0.92mentions of Amneal Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.51 to $0.53 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.32 out of 5 stars

Medical Sector

833rd out of 932 stocks

Pharmaceutical Preparations Industry

393rd out of 437 stocks

AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

Amneal: Q1 Earnings Snapshot
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.35 per share
Book Value
($0.21) per share


Free Float
Market Cap
$2.09 billion
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

4 analysts have issued 12-month price targets for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $8.00 to $9.00. On average, they expect the company's stock price to reach $8.25 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 at the beginning of 2024. Since then, AMRX stock has increased by 11.7% and is now trading at $6.78.
View the best growth stocks for 2024 here

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,070,000 shares, an increase of 29.5% from the April 30th total of 2,370,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is currently 1.9 days. Currently, 2.8% of the company's stock are sold short.
View Amneal Pharmaceuticals' Short Interest

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024.
View our AMRX earnings forecast

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced its quarterly earnings results on Friday, May, 3rd. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.04. The company earned $659.19 million during the quarter, compared to analysts' expectations of $623.08 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 234.06% and a negative net margin of 6.76%.

What ETFs hold Amneal Pharmaceuticals' stock?
What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of 0.530-0.630 for the period, compared to the consensus estimate of 0.580. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.6 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.47%), LSV Asset Management (0.35%), Hillsdale Investment Management Inc. (0.23%), Assenagon Asset Management S.A. (0.18%), Jacobs Levy Equity Management Inc. (0.11%) and Sanders Morris Harris LLC (0.08%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 5/30/2024 by Staff

From Our Partners